Symbols / LGVN Stock $0.73 -8.75% Longeveron Inc.
LGVN (Stock) Chart
Stock Fundamentals
|
|
|
|
|
|
About
Official websiteLongeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 3 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer's disease, as well as in phase 2b clinical trial to treat aging frailty. The company was incorporated in 2014 and is headquartered in Miami, Florida.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-05-11 | down | Maxim Group | Buy → Hold | — |
| 2026-05-04 | main | HC Wainwright & Co. | Buy → Buy | $8 |
| 2025-08-15 | main | Roth Capital | Buy → Buy | $3 |
| 2025-03-21 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2025-03-03 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2024-12-05 | init | Roth MKM | — → Buy | $10 |
| 2024-11-25 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2024-11-04 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2024-09-04 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2024-08-27 | main | Maxim Group | Buy → Buy | $6 |
| 2024-08-15 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2024-07-31 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2024-07-29 | main | HC Wainwright & Co. | Buy → Buy | $10 |
| 2024-05-17 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2024-04-29 | main | HC Wainwright & Co. | Buy → Buy | $12 |
| 2023-12-04 | init | HC Wainwright & Co. | — → Buy | $6 |
| 2023-05-16 | reit | EF Hutton | Buy → Buy | $13 |
| 2023-05-09 | reit | EF Hutton | — → Buy | $13 |
| 2023-03-27 | reit | EF Hutton | — → Buy | $13 |
| 2023-01-10 | main | EF Hutton | — → Buy | $13 |
- Longeveron (NASDAQ: LGVN) CFO Lisa Locklear to step down, controller eyed as successor - Stock Titan Fri, 05 Jun 2026 20
- LGVN Stock Slips After Hours As FDA Flags Concerns On Rare Heart Defect Trial Design - Stocktwits Sat, 09 May 2026 00
- A $30 Million Reason to Buy Penny Stock Longeveron Today - Yahoo Finance Wed, 11 Mar 2026 07
- LONGEVERON ($LGVN) Releases Q4 2025 Earnings, Stock Rises - Quiver Quantitative ue, 17 Mar 2026 07
- Stem cell firm Longeveron seeks Alzheimer’s, heart partners at BIO 2026 - Stock Titan hu, 04 Jun 2026 13
- LGVN stock slips after hours as FDA flags concerns on rare heart defect trial design - MSN Sun, 10 May 2026 09
- Longeveron Announces 2026 First Quarter Financial Results and Provides Business Update - GlobeNewswire Wed, 13 May 2026 07
- Longeveron jumps 70.7% as investors react to up to $30M private placement financing | LGVN Stock News - Quiver Quantitative ue, 10 Mar 2026 07
- Longeveron Issues Letter to Stockholders Highlighting - GlobeNewswire Wed, 20 May 2026 07
- LGVN Shares Rise After Investigational Therapy Shows Improvement In Age-Related Frailty Study - Stocktwits Wed, 25 Feb 2026 16
- Inside Longeveron’s stem-cell push on a deadly infant heart defect - Stock Titan Wed, 20 May 2026 07
- Stem cell bet on rare heart defect: Longeveron eyes 2026 trial results - Stock Titan ue, 17 Mar 2026 07
- Longeveron secures $15M now, another $15M tied to HLHS trial milestones - Stock Titan ue, 10 Mar 2026 07
- Longeveron plans May 13 business update after market close - Stock Titan ue, 05 May 2026 07
- Biotech Longeveron secures $15M, cash runway past 2026 HLHS trial readout - Stock Titan Wed, 11 Mar 2026 07
Insider Transactions
Financials
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
1.20
-49.87%
|
2.39
+237.38%
|
0.71
-41.98%
|
1.22
|
| Operating Revenue |
|
1.20
-49.87%
|
2.39
+237.38%
|
0.71
-41.98%
|
1.22
|
| Cost Of Revenue |
|
0.40
-22.05%
|
0.51
+4.10%
|
0.49
-32.69%
|
0.72
|
| Reconciled Cost Of Revenue |
|
0.40
-22.05%
|
0.51
+4.10%
|
0.49
-32.69%
|
0.72
|
| Gross Profit |
|
0.80
-57.38%
|
1.88
+752.49%
|
0.22
-55.53%
|
0.50
|
| Operating Expense |
|
24.09
+30.88%
|
18.41
-13.38%
|
21.25
+14.62%
|
18.54
|
| Research And Development |
|
12.04
+47.98%
|
8.14
-10.25%
|
9.07
-3.24%
|
9.37
|
| Selling General And Administration |
|
12.05
+17.33%
|
10.27
-15.72%
|
12.18
+32.87%
|
9.17
|
| Selling And Marketing Expense |
|
—
|
—
|
0.78
-25.50%
|
1.05
|
| General And Administrative Expense |
|
12.05
+17.33%
|
10.27
-15.72%
|
12.18
+50.07%
|
8.12
|
| Other Gand A |
|
12.05
+17.33%
|
10.27
-15.72%
|
12.18
+50.07%
|
8.12
|
| Total Expenses |
|
24.49
+29.46%
|
18.91
-12.99%
|
21.74
+12.84%
|
19.27
|
| Operating Income |
|
-23.29
-40.95%
|
-16.52
+21.43%
|
-21.03
-16.55%
|
-18.04
|
| Total Operating Income As Reported |
|
-23.29
-40.95%
|
-16.52
+21.43%
|
-21.03
-16.55%
|
-18.04
|
| EBITDA |
|
-22.06
-41.74%
|
-15.56
+22.50%
|
-20.08
-17.10%
|
-17.15
|
| Normalized EBITDA |
|
-21.96
-41.12%
|
-15.56
+22.39%
|
-20.05
-27.30%
|
-15.75
|
| Reconciled Depreciation |
|
1.23
+27.97%
|
0.96
+1.27%
|
0.95
+5.94%
|
0.89
|
| EBIT |
|
-23.29
-40.95%
|
-16.52
+21.43%
|
-21.03
-16.55%
|
-18.04
|
| Total Unusual Items |
|
-0.10
|
0.00
+100.00%
|
-0.03
+97.85%
|
-1.40
|
| Total Unusual Items Excluding Goodwill |
|
-0.10
|
0.00
+100.00%
|
-0.03
+97.85%
|
-1.40
|
| Special Income Charges |
|
-0.10
|
0.00
+100.00%
|
-0.03
+97.85%
|
-1.40
|
| Other Special Charges |
|
—
|
—
|
0.03
-97.85%
|
1.40
|
| Net Income |
|
-22.70
-42.14%
|
-15.97
+25.41%
|
-21.41
-13.69%
|
-18.84
|
| Pretax Income |
|
-22.70
-42.14%
|
-15.97
+25.41%
|
-21.41
-13.69%
|
-18.84
|
| Net Non Operating Interest Income Expense |
|
—
|
—
|
—
|
0.00
|
| Interest Expense Non Operating |
|
—
|
—
|
—
|
0.00
|
| Net Interest Income |
|
—
|
—
|
—
|
0.00
|
| Interest Expense |
|
—
|
—
|
—
|
0.00
|
| Other Income Expense |
|
0.58
+6.19%
|
0.55
+242.97%
|
-0.38
+51.52%
|
-0.79
|
| Other Non Operating Income Expenses |
|
0.68
+23.86%
|
0.55
+255.08%
|
-0.35
-158.42%
|
0.61
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-22.70
-42.14%
|
-15.97
+25.41%
|
-21.41
-13.69%
|
-18.84
|
| Net Income From Continuing Operation Net Minority Interest |
|
-22.70
-42.14%
|
-15.97
+25.41%
|
-21.41
-13.69%
|
-18.84
|
| Net Income From Continuing And Discontinued Operation |
|
-22.70
-42.14%
|
-15.97
+25.41%
|
-21.41
-13.69%
|
-18.84
|
| Net Income Continuous Operations |
|
-22.70
-42.14%
|
-15.97
+25.41%
|
-21.41
-13.69%
|
-18.84
|
| Normalized Income |
|
-22.61
-41.53%
|
-15.97
+25.30%
|
-21.38
-22.63%
|
-17.44
|
| Net Income Common Stockholders |
|
-22.70
+7.79%
|
-24.62
-10.86%
|
-22.21
-17.92%
|
-18.84
|
| Otherunder Preferred Stock Dividend |
|
0.00
-100.00%
|
8.65
+983.96%
|
0.80
|
0.00
|
| Diluted EPS |
|
-1.29
+50.76%
|
-2.62
+74.36%
|
-10.22
-13.56%
|
-9.00
|
| Basic EPS |
|
-1.29
+50.76%
|
-2.62
+74.36%
|
-10.22
-13.56%
|
-9.00
|
| Basic Average Shares |
|
17.58
+86.76%
|
9.41
+333.00%
|
2.17
+3.65%
|
2.10
|
| Diluted Average Shares |
|
17.58
+86.76%
|
9.41
+333.00%
|
2.17
+3.65%
|
2.10
|
| Diluted NI Availto Com Stockholders |
|
-22.70
+7.79%
|
-24.62
-10.86%
|
-22.21
-17.92%
|
-18.84
|
| Gain On Sale Of PPE |
|
-0.10
|
0.00
|
—
|
—
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
10.26
-59.85%
|
25.56
+111.61%
|
12.08
-55.94%
|
27.41
|
| Current Assets |
|
5.45
-72.22%
|
19.62
+235.57%
|
5.85
-71.16%
|
20.28
|
| Cash Cash Equivalents And Short Term Investments |
|
4.66
-75.76%
|
19.23
+258.74%
|
5.36
-72.73%
|
19.66
|
| Cash And Cash Equivalents |
|
4.66
-75.76%
|
19.23
+288.60%
|
4.95
-52.88%
|
10.50
|
| Other Short Term Investments |
|
—
|
0.00
-100.00%
|
0.41
-95.50%
|
9.15
|
| Receivables |
|
0.10
+23.81%
|
0.08
-24.32%
|
0.11
-49.08%
|
0.22
|
| Accounts Receivable |
|
0.10
+316.00%
|
0.03
+66.67%
|
0.01
|
0.00
|
| Other Receivables |
|
—
|
0.06
-38.54%
|
0.10
-55.96%
|
0.22
|
| Prepaid Assets |
|
—
|
—
|
—
|
—
|
| Current Deferred Assets |
|
—
|
—
|
—
|
—
|
| Other Current Assets |
|
0.69
+122.73%
|
0.31
-18.09%
|
0.38
-6.93%
|
0.40
|
| Total Non Current Assets |
|
4.81
-18.94%
|
5.93
-4.75%
|
6.23
-12.66%
|
7.13
|
| Net PPE |
|
2.35
-29.48%
|
3.33
-11.17%
|
3.75
-16.29%
|
4.48
|
| Gross PPE |
|
8.17
-3.92%
|
8.51
+3.85%
|
8.19
+82.81%
|
4.48
|
| Accumulated Depreciation |
|
-5.82
-12.54%
|
-5.17
-16.53%
|
-4.44
-19.13%
|
-3.73
|
| Properties |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Buildings And Improvements |
|
0.51
-41.84%
|
0.88
-27.76%
|
1.22
-20.25%
|
1.53
|
| Machinery Furniture Equipment |
|
3.25
+0.87%
|
3.22
+21.96%
|
2.64
+12.48%
|
2.35
|
| Other Properties |
|
—
|
0.88
-27.76%
|
1.22
-58.60%
|
2.95
|
| Leases |
|
4.41
+0.18%
|
4.40
+1.71%
|
4.33
+0.00%
|
4.33
|
| Goodwill And Other Intangible Assets |
|
2.29
-4.83%
|
2.40
+4.98%
|
2.29
-5.06%
|
2.41
|
| Other Intangible Assets |
|
2.29
-4.83%
|
2.40
+4.98%
|
2.29
-5.06%
|
2.41
|
| Other Non Current Assets |
|
0.18
-12.87%
|
0.20
+4.66%
|
0.19
-20.90%
|
0.24
|
| Total Liabilities Net Minority Interest |
|
4.59
+24.93%
|
3.67
-31.22%
|
5.34
-22.76%
|
6.91
|
| Current Liabilities |
|
4.09
+58.29%
|
2.58
-33.61%
|
3.89
-20.13%
|
4.87
|
| Payables And Accrued Expenses |
|
3.39
+76.76%
|
1.92
-31.22%
|
2.79
+16.20%
|
2.40
|
| Payables |
|
0.42
+327.27%
|
0.10
-84.48%
|
0.64
-63.56%
|
1.75
|
| Accounts Payable |
|
0.42
+327.27%
|
0.10
-84.48%
|
0.64
-63.56%
|
1.75
|
| Current Accrued Expenses |
|
2.97
+63.13%
|
1.82
-15.43%
|
2.15
+231.08%
|
0.65
|
| Current Debt And Capital Lease Obligation |
|
0.66
+5.14%
|
0.62
+5.06%
|
0.59
+5.14%
|
0.56
|
| Current Capital Lease Obligation |
|
0.66
+5.14%
|
0.62
+5.06%
|
0.59
+5.14%
|
0.56
|
| Current Deferred Liabilities |
|
0.04
+0.00%
|
0.04
-92.09%
|
0.51
+0.00%
|
0.51
|
| Current Deferred Revenue |
|
0.04
+0.00%
|
0.04
-92.09%
|
0.51
+0.00%
|
0.51
|
| Other Current Liabilities |
|
—
|
—
|
—
|
1.40
|
| Total Non Current Liabilities Net Minority Interest |
|
0.50
-54.18%
|
1.09
-24.79%
|
1.45
-29.05%
|
2.04
|
| Long Term Debt And Capital Lease Obligation |
|
0.17
-79.49%
|
0.82
-43.09%
|
1.45
-29.05%
|
2.04
|
| Long Term Capital Lease Obligation |
|
0.17
-79.49%
|
0.82
-43.09%
|
1.45
-29.05%
|
2.04
|
| Other Non Current Liabilities |
|
0.33
+24.53%
|
0.27
|
—
|
—
|
| Stockholders Equity |
|
5.67
-74.07%
|
21.89
+224.68%
|
6.74
-67.12%
|
20.50
|
| Common Stock Equity |
|
5.67
-74.07%
|
21.89
+224.68%
|
6.74
-67.12%
|
20.50
|
| Capital Stock |
|
0.02
+57.14%
|
0.01
+600.00%
|
0.00
-90.48%
|
0.02
|
| Common Stock |
|
0.02
+57.14%
|
0.01
+600.00%
|
0.00
-90.48%
|
0.02
|
| Preferred Stock |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Share Issued |
|
22.93
+53.98%
|
14.89
+493.11%
|
2.51
+19.45%
|
2.10
|
| Ordinary Shares Number |
|
22.93
+53.98%
|
14.89
+493.11%
|
2.51
+19.45%
|
2.10
|
| Additional Paid In Capital |
|
137.96
+4.93%
|
131.48
+43.19%
|
91.82
+9.69%
|
83.71
|
| Retained Earnings |
|
-132.31
-20.71%
|
-109.61
-28.97%
|
-84.98
-35.38%
|
-62.77
|
| Gains Losses Not Affecting Retained Earnings |
|
—
|
—
|
0.00
+100.00%
|
-0.36
|
| Other Equity Adjustments |
|
—
|
—
|
—
|
-0.36
|
| Total Equity Gross Minority Interest |
|
5.67
-74.07%
|
21.89
+224.68%
|
6.74
-67.12%
|
20.50
|
| Total Capitalization |
|
5.67
-74.07%
|
21.89
+224.68%
|
6.74
-67.12%
|
20.50
|
| Working Capital |
|
1.36
-92.00%
|
17.04
+769.93%
|
1.96
-87.29%
|
15.41
|
| Invested Capital |
|
5.67
-74.07%
|
21.89
+224.68%
|
6.74
-67.12%
|
20.50
|
| Total Debt |
|
0.82
-43.05%
|
1.45
-29.10%
|
2.04
-21.65%
|
2.60
|
| Capital Lease Obligations |
|
0.82
-43.05%
|
1.45
-29.10%
|
2.04
-21.65%
|
2.60
|
| Net Tangible Assets |
|
3.39
-82.60%
|
19.49
+337.49%
|
4.45
-75.38%
|
18.09
|
| Tangible Book Value |
|
3.39
-82.60%
|
19.49
+337.49%
|
4.45
-75.38%
|
18.09
|
| Current Notes Payable |
|
—
|
—
|
—
|
—
|
| Other Equity Interest |
|
—
|
—
|
-0.10
+0.00%
|
-0.10
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-18.64
-34.45%
|
-13.87
+27.02%
|
-19.00
-36.03%
|
-13.97
|
| Cash Flow From Continuing Operating Activities |
|
-18.64
-34.45%
|
-13.87
+27.02%
|
-19.00
-36.03%
|
-13.97
|
| Net Income From Continuing Operations |
|
-22.70
-42.14%
|
-15.97
+25.41%
|
-21.41
-13.69%
|
-18.84
|
| Depreciation Amortization Depletion |
|
1.23
+27.97%
|
0.96
+1.27%
|
0.95
+5.94%
|
0.89
|
| Depreciation And Amortization |
|
1.23
+27.97%
|
0.96
+1.27%
|
0.95
+5.94%
|
0.89
|
| Other Non Cash Items |
|
—
|
—
|
-1.40
|
—
|
| Stock Based Compensation |
|
1.68
-27.96%
|
2.33
+14.57%
|
2.03
-6.23%
|
2.17
|
| Asset Impairment Charge |
|
—
|
0.00
-100.00%
|
0.29
|
0.00
|
| Operating Gains Losses |
|
0.10
|
—
|
—
|
1.40
|
| Gain Loss On Investment Securities |
|
—
|
—
|
—
|
1.40
|
| Unrealized Gain Loss On Investment Securities |
|
—
|
—
|
0.22
+29.41%
|
0.17
|
| Gain Loss On Sale Of PPE |
|
—
|
—
|
—
|
0.00
|
| Change In Working Capital |
|
1.06
+185.33%
|
-1.24
-486.60%
|
0.32
+34.87%
|
0.24
|
| Change In Receivables |
|
-0.02
-174.07%
|
0.03
-74.77%
|
0.11
+165.24%
|
-0.16
|
| Change In Prepaid Assets |
|
-0.38
-655.88%
|
0.07
+142.86%
|
0.03
+122.95%
|
-0.12
|
| Change In Payables And Accrued Expense |
|
1.62
+285.78%
|
-0.87
-324.16%
|
0.39
-9.32%
|
0.43
|
| Change In Accrued Expense |
|
1.29
+490.06%
|
-0.33
-122.10%
|
1.50
+321.86%
|
-0.68
|
| Change In Payable |
|
0.33
+160.19%
|
-0.54
+51.48%
|
-1.11
-200.63%
|
1.11
|
| Change In Account Payable |
|
0.33
+160.19%
|
-0.54
+51.48%
|
-1.11
-200.63%
|
1.11
|
| Change In Other Working Capital |
|
-0.25
+64.72%
|
-0.72
-183.46%
|
-0.25
-330.91%
|
0.11
|
| Change In Other Current Assets |
|
0.03
+377.78%
|
-0.01
-117.65%
|
0.05
+440.00%
|
-0.01
|
| Change In Other Current Liabilities |
|
0.07
-75.09%
|
0.27
|
0.00
|
—
|
| Investing Cash Flow |
|
-0.59
+7.03%
|
-0.64
-107.82%
|
8.19
+1309.16%
|
-0.68
|
| Cash Flow From Continuing Investing Activities |
|
-0.59
+7.03%
|
-0.64
-107.82%
|
8.19
+1309.16%
|
-0.68
|
| Net PPE Purchase And Sale |
|
-0.24
+62.60%
|
-0.66
-117.61%
|
-0.30
+47.10%
|
-0.57
|
| Purchase Of PPE |
|
-0.24
+62.60%
|
-0.66
-117.61%
|
-0.30
+47.10%
|
-0.57
|
| Sale Of PPE |
|
—
|
—
|
—
|
0.00
|
| Capital Expenditure |
|
-0.59
+40.02%
|
-0.99
-42.94%
|
-0.69
+18.93%
|
-0.86
|
| Net Investment Purchase And Sale |
|
0.00
-100.00%
|
0.35
-96.04%
|
8.88
+4860.89%
|
0.18
|
| Sale Of Investment |
|
0.00
-100.00%
|
0.35
-96.04%
|
8.88
|
—
|
| Net Intangibles Purchase And Sale |
|
-0.35
-3.86%
|
-0.34
+14.25%
|
-0.39
-36.93%
|
-0.29
|
| Purchase Of Intangibles |
|
-0.35
-3.86%
|
-0.34
+14.25%
|
-0.39
-36.93%
|
-0.29
|
| Financing Cash Flow |
|
4.67
-83.78%
|
28.79
+447.15%
|
5.26
+1133.79%
|
-0.51
|
| Cash Flow From Continuing Financing Activities |
|
4.67
-83.78%
|
28.79
+447.15%
|
5.26
+1133.79%
|
-0.51
|
| Net Issuance Payments Of Debt |
|
—
|
—
|
—
|
0.00
|
| Issuance Of Debt |
|
—
|
—
|
—
|
—
|
| Repayment Of Debt |
|
—
|
—
|
—
|
0.00
|
| Long Term Debt Issuance |
|
—
|
—
|
—
|
—
|
| Long Term Debt Payments |
|
—
|
—
|
—
|
0.00
|
| Net Long Term Debt Issuance |
|
—
|
—
|
—
|
0.00
|
| Short Term Debt Issuance |
|
—
|
—
|
—
|
—
|
| Short Term Debt Payments |
|
—
|
—
|
—
|
0.00
|
| Net Short Term Debt Issuance |
|
—
|
—
|
—
|
0.00
|
| Net Common Stock Issuance |
|
4.98
-61.29%
|
12.87
+141.03%
|
5.34
|
0.00
|
| Proceeds From Stock Option Exercised |
|
0.00
-100.00%
|
16.19
+16421.43%
|
0.10
+4800.00%
|
0.00
|
| Net Other Financing Charges |
|
-0.31
-16.92%
|
-0.27
-52.87%
|
-0.17
+65.95%
|
-0.51
|
| Changes In Cash |
|
-14.57
-202.02%
|
14.28
+357.17%
|
-5.55
+63.35%
|
-15.15
|
| Beginning Cash Position |
|
19.23
+288.60%
|
4.95
-52.88%
|
10.50
-59.07%
|
25.66
|
| End Cash Position |
|
4.66
-75.76%
|
19.23
+288.60%
|
4.95
-52.88%
|
10.50
|
| Free Cash Flow |
|
-19.24
-29.48%
|
-14.86
+24.55%
|
-19.70
-32.86%
|
-14.82
|
| Common Stock Issuance |
|
4.98
-61.29%
|
12.87
+141.03%
|
5.34
|
0.00
|
| Interest Received CFO |
|
0.00
-100.00%
|
0.06
-72.73%
|
0.22
|
—
|
| Issuance Of Capital Stock |
|
4.98
-61.29%
|
12.87
+141.03%
|
5.34
|
0.00
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 8-K2026-06-05 View
- 8-K2026-05-13 View
- 10-Q2026-05-13 View
- 8-K2026-05-08 View
- 42026-05-05 View
- 42026-05-05 View
- 42026-05-05 View
- 42026-05-05 View
- 42026-05-05 View
- 8-K2026-04-10 View
- 42026-04-03 View
- 42026-04-03 View
- 42026-04-03 View
- 42026-04-03 View
- 42026-04-03 View
- 8-K2026-03-25 View
- 8-K2026-03-24 View
- 10-K2026-03-17 View
- 42026-03-13 View
- 8-K2026-03-12 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|